On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lily has announced positive topline results from the novel TOGETHER-PsA open-label Phase IIIb trial evaluating ...

Taltz (ixekizumab) is a prescription drug used to treat certain inflammatory conditions, including plaque psoriasis. This drug comes as a liquid solution that’s given as an injection under the skin.

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan 8 (Reuters) - Eli Lilly said on Thursday a late-stage trial showed ...